Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLNCF) EBT (2019 - 2025)

Historic EBT for Silence Therapeutics (SLNCF) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' EBT rose 4095.79% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.2 million, marking a year-over-year increase of 1514.58%. This contributed to the annual value of -$44.5 million for FY2024, which is 1653.4% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' EBT is -$21.0 million, which was up 4095.79% from -$27.3 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' EBT registered a high of $12.6 million during Q4 2024, and its lowest value of -$35.5 million during Q3 2024.
  • Over the past 5 years, Silence Therapeutics' median EBT value was -$16.6 million (recorded in 2021), while the average stood at -$16.1 million.
  • In the last 5 years, Silence Therapeutics' EBT surged by 16797.28% in 2024 and then tumbled by 127959.38% in 2025.
  • Over the past 5 years, Silence Therapeutics' EBT (Quarter) stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then skyrocketed by 167.97% to $12.6 million in 2024, then crashed by 265.98% to -$21.0 million in 2025.
  • Its last three reported values are -$21.0 million in Q3 2025, -$27.3 million for Q2 2025, and -$28.5 million during Q1 2025.